Canada· CA-DIN-02537206
BEYFORTUS
A nirsevimab product containing nirsevimab, registered in Canada by SANOFI PASTEUR LIMITED. The same ATC class is registered in 14 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Nirsevimab is registered in 14 of 19 countries.
Countries holding a registration under ATC J06BD08 (nirsevimab), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 9 of them publish a price we can compare per daily dose
Nirsevimab · ATC J06BD08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- NIRSEVIMAB
- Manufacturer
- SANOFI PASTEUR LIMITED
- Country
- Canada (CA)
- ATC code
- J06BD08
- ATC class
- Nirsevimab
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nirsevimab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBEYFORTUSSanofi Winthrop Industrie, Gentilly
- United StatesBEYFORTUSSanofi Vaccines US Inc.
- FinlandBeyfortusOrifarm Oy
- SwitzerlandBeyfortus
- BelgiumBeyfortus 100 mgSanofi Winthrop Industrie
- IcelandBeyfortusSanofi Winthrop Industrie
- Japanニルセビマブ（遺伝子組換え）サノフィ
- NetherlandsBeyfortus 100 mg, oplossing voor injectie in een voorgevulde spuitSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Beyfortus
- Liechtenstein · Beyfortus
- Norway · Beyfortus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/caf20b07-531c-4a5f-80a2-08f0a637d91a GET /v1/drugs/caf20b07-531c-4a5f-80a2-08f0a637d91a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02537206",
"form": "SOLUTION",
"class": "Human",
"routes": [
"INTRAMUSCULAR"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "J06BD08",
"schedule": [
"Schedule D"
],
"drug_code": "102594",
"strengths": [
"50 MG"
],
"ahfs_class": null,
"substances": [
"NIRSEVIMAB"
],
"product_categorization": null
}See everything about nirsevimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.